荣誉与大事记

● CMG901 for the treatment of gastric 

cancer and gastroesophageal junction

 adenocarcinoma was granted the 

Orphan-drug Designation by the FDA.

● FDA granted CMG901 Fast Track

 Designation for unresectable or metastatic

 gastric and gastroesophageal junction 

cancer which have relapsed and/or are 

refractory to approved therapies.

● Keymed Biosciences was included as eligible 

stocks of the Shenzhen-Hong Kong Stock Connect.

● Keymed Biosciences released positive result from 

Phase II clinical trial of CM310 at CRSwNP.

● CM350 was approved for clinical trial by NMPA.

● The first patient was dosed in clinical trial of CM355 

   a CD20xCD3 bispecificantibody developed by a joint

   venture between Keymed and InnoCare called Tiannuojiancheng 

   Biopharma, for the treatment of CD20+ B-cell malignancies.

● CM338 was approved for clinical trial by NMPA.

● CM326 for AD was approved for clinical trial by NMPA.

● Keymed entered into an agreement with CSPC in relation to the 

   exclusive licensing and commercialization of the product CM326 

   in the  treatment of moderate to severe asthma, chronic 

   obstructive pulmonary disease (COPD) and other respiratory

   system diseases.

● The Phase IIb clinical study of  CM310 recombinant humanized 

   monoclonal antibody injection (CM310AD002) has completed

   the analysis of unblinded data with preliminary statistics,

   showing positive results. 

● CM336 was approved for clinical trials by NMPA.

● CM355 was approved for clinical trials by NMPA.

● Keymed Biosciences Inc. was listed on the Main Board 

   of The Stock Exchange of Hong Kong Limited under the stock 

   code “2162”.

● CM326 was approved for clinical trials by NMPA.

● CMG901 was approved for clinical trials by FDA.

● Keymed entered into an agreement with CSPC in relation to the exclusive licensing and commercialization of the product CM310 in the treatment of moderate to severe asthma, chronic  obstructive pulmonary disease (COPD) and other respiratory 

system diseases .

● CMG901 was approved for clinical trials in October and administered to the first patient in December.

● CM313 was approved for clinical trials in November.

● Phase IIb clinical trial was initiated in November to evaluate the effect of CM310 in patients with moderate to severe atopicdermatitis, and phase II trial was initiated in December to evaluatethe effect of CM310 in patients with chronic sinusitis with polyps.

● In May 2020, CM312 was approved for clinical trials by NMPA.

● Phase Ib/IIa clinical trial was initiated in June to evaluate the effect of CM310 in patients with moderate to severe atopic dermatitis.

● CM310 was approved for clinical trials in July, and the phase I trial was initiated in September.

● Established in Chengdu as an innovative medicine R&D company.